Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 15/20 | 0.51 |
| ▸ | APOB | P04114 | 9/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042807 | 0.92 | MTTP (0.49) | MTTPAPOBGAASMN1; SMN2KDM4E | |
| SCHEMBL7042911 | 0.91 | MTTP (0.50) | MTTPAPOBGAAKDM4E | |
| SCHEMBL6255815 | 0.87 | MTTP (0.53) | MTTPAPOBGAASMN1; SMN2KDM4E | |
| SCHEMBL7035904 | 0.87 | MTTP (0.49) | MTTPAPOBGAA | |
| SCHEMBL7039772 | 0.87 | MTTP (0.53) | MTTPAPOBGAA | |
| SCHEMBL7043296 | 0.87 | MTTP (0.57) | MTTPAPOBGAA | |
| SCHEMBL6674929 | 0.86 | MTTP (0.49) | MTTPAPOBGAASMN1; SMN2KDM4E | |
| SCHEMBL7039849 | 0.86 | APOB (0.50) | MTTPAPOBKDM4E | |
| SCHEMBL6278519 | 0.85 | MTTP (0.55) | MTTPAPOBGAASMN1; SMN2KDM4E | |
| SCHEMBL7041096 | 0.84 | MTTP (0.51) | MTTPAPOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885APOB 1/4885GAA 276/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | MTTP 1/4885APOB 18/4885GAA 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.